ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting

rights
01/31/202471,751,20177,686,818

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980,

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

Attachment



EN
02/02/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis’ Annual Shareholders General Meeting to be Held on June 26, ...

Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025 NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participation in t...

May 21, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

L’Assemblée Générale Mixte de Cellectis se tiendra le 26 juin 2025

L’Assemblée Générale Mixte de Cellectis se tiendra le 26 juin 2025 NEW YORK, 21 mai 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, annonce la tenue de son Assemblée Générale Mixte le 26 juin 2025 à 14h30, heure de Paris, à l’auditorium du site Biopark, situé au 11 rue Watt, 4ème étage, 75013 Paris, France. La brochure de convocation comportant l’ordre du jour et ...

May 21, 2025 1 EN
Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 EN
Christophe-Raphaël Ganet ... (+2)
  • Christophe-Raphaël Ganet
  • Stephane Beyazian
FRA FRAPORT AG
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
05/13/25 May 13, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
05/13/25 May 13, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch